CORE1: PHASE 2, SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)

被引：0
|
作者：
Li, Roger
Steinberg, Gary
Lamm, Donald
Uchio, Ed M.
Shah, Paras
Kamat, Ashish M.
Hnat, Nataliya
Chisamore, Michael J.
Grandi, Paola
Burke, James
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP54-03
引用
收藏
页码：E927 / E927
页数：1
相关论文
共 50 条
  • [21] Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
    Cooper, Owen Alan Edwards
    Ghatnekar, Ola
    Piglowska, Natalia
    Smith, Charlie A.
    Swinburn, Paul
    Catto, James W. F.
    Niegisch, Guenter
    Jakobsen, Jorn Skibsted
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (03) : 469 - 477
  • [22] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2023, 83 : S748 - S748
  • [23] PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN
    Kulkarini, Girish S.
    de Wit, Ronald
    Balar, Arjun V.
    Kamat, Ashish
    Uchio, Edward
    Mourey, Loic
    Krieger, Laurence
    Singer, Eric A.
    Bajorin, Dean
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuku
    Konety, Badarinath
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    Boormans, Joost L.
    [J]. JOURNAL OF UROLOGY, 2019, 201 (04): : E616 - E616
  • [24] HEALTHCARE RESOURCE USE (HCRU) OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS POST BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE STATUS IN MULTIPLE COUNTRIES
    Broughton, E.
    Chun, D.
    Gooden, K.
    Mycock, K.
    Rajkovic, I
    Taylor-Stokes, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S484 - S485
  • [25] A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
    Packiam, Vignesh T.
    Campanile, Alexa N.
    Barocas, Daniel A.
    Chamie, Karim
    Davis, Ronald L., III
    Kader, A. Karim
    Lamm, Donald L.
    Yeung, Alex W.
    Steinberg, Gary D.
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E142 - E142
  • [26] Role of immunotherapy in Bacillus Calmette-Guerin unresponsive: non-muscle invasive bladder cancer
    Suh, Jungyo
    Yoo, Sangjun
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (10) : 6537 - 6545
  • [27] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [28] Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).
    Balar, Arjun Vasant
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost
    Mourey, Loic
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [29] A phase 1 dose-escalation trial of intravesical CG0070 for superficial transitional cell carcinoma (TCC) of the bladder after bacillus Calmette-Guerin (BCG) failure
    Lamm, D
    Stephenson, J
    Tsai, H
    Nemunaitis, J
    Goldstein, M
    Arseneau, J
    Neal, K
    Aimi, J
    Yu, D
    Corman, JM
    McKiernan, JM
    Senzer, N
    Burke, JP
    [J]. JOURNAL OF UROLOGY, 2006, 175 (04): : 272 - 272
  • [30] Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Gupta, S.
    Kulkarni, G.
    Necchi, A.
    Shore, N. D.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2024, 85 : S433 - S433
12345